228 related articles for article (PubMed ID: 2127341)
21. Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis.
Miyagawa S; Kamata R; Matsumoto K; Okamura R; Maeda H
Graefes Arch Clin Exp Ophthalmol; 1994 Aug; 232(8):488-93. PubMed ID: 7926884
[TBL] [Abstract][Full Text] [Related]
22. Pseudomonas aeruginosa MucD protease mediates keratitis by inhibiting neutrophil recruitment and promoting bacterial survival.
Mochizuki Y; Suzuki T; Oka N; Zhang Y; Hayashi Y; Hayashi N; Gotoh N; Ohashi Y
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):240-6. PubMed ID: 24255043
[TBL] [Abstract][Full Text] [Related]
23. Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.
Clemens LE; Jaynes J; Lim E; Kolar SS; Reins RY; Baidouri H; Hanlon S; McDermott AM; Woodburn KW
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6273-6281. PubMed ID: 29242901
[TBL] [Abstract][Full Text] [Related]
24. In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection.
Kernacki KA; Hobden JA; Hazlett LD; Fridman R; Berk RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1371-8. PubMed ID: 7775115
[TBL] [Abstract][Full Text] [Related]
25. Enoxacin therapy for experimental pseudomonas keratitis.
Esposito S; Thadepalli H; Benler HA; Chuah SK
J Chemother; 1991 Jun; 3(3):147-51. PubMed ID: 1919652
[TBL] [Abstract][Full Text] [Related]
26. Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis.
Tajima K; Miyake T; Koike N; Hattori T; Takahashi H; Matsumoto T; Fujita K; Kuroda M; Ito N; Goto H
J Ocul Pharmacol Ther; 2015 Dec; 31(10):636-41. PubMed ID: 26348840
[TBL] [Abstract][Full Text] [Related]
27. Keratotomy model of pseudomonas keratitis: gentamicin chemotherapy.
Brockman EB; Tarantino PA; Hobden JA; Hill JM; O'Callaghan RJ; Kaufman HE; Insler MS
Refract Corneal Surg; 1992; 8(1):39-43. PubMed ID: 1554638
[TBL] [Abstract][Full Text] [Related]
28. Pseudomonas keratitis: protease IV gene conservation, distribution, and production relative to virulence and other Pseudomonas proteases.
Caballero A; Thibodeaux B; Marquart M; Traidej M; O'Callaghan R
Invest Ophthalmol Vis Sci; 2004 Feb; 45(2):522-30. PubMed ID: 14744894
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of ovomacroglobulin on bacterial keratitis in rabbits.
Miyagawa S; Kamata R; Matsumoto K; Okamura R; Maeda H
Graefes Arch Clin Exp Ophthalmol; 1991; 229(3):281-6. PubMed ID: 1869068
[TBL] [Abstract][Full Text] [Related]
30. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
[TBL] [Abstract][Full Text] [Related]
31. Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eyes using gentamicin-loaded hydrogels.
Frucht-Pery J; Raiskup F; Mechoulam H; Shapiro M; Eljarrat-Binstock E; Domb A
Cornea; 2006 Dec; 25(10):1182-6. PubMed ID: 17172895
[TBL] [Abstract][Full Text] [Related]
32. Predatory bacteria can reduce Pseudomonas aeruginosa induced corneal perforation and proliferation in a rabbit keratitis model.
Romanowski EG; Stella NA; Brazile BL; Lathrop KL; Franks JM; Sigal IA; Kim T; Elsayed M; Kadouri DE; Shanks RMQ
Ocul Surf; 2023 Apr; 28():254-261. PubMed ID: 37146902
[TBL] [Abstract][Full Text] [Related]
33. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa proteases and corneal virulence.
Hobden JA
DNA Cell Biol; 2002; 21(5-6):391-6. PubMed ID: 12167241
[TBL] [Abstract][Full Text] [Related]
35. The effect of tuftsin in the treatment of experimental Pseudomonas keratitis.
Smith PC; Zam ZS; Stern GA
Cornea; 1986; 5(3):181-3. PubMed ID: 2980837
[No Abstract] [Full Text] [Related]
36. Ocular Permeation of Topical Tazocin and Its Effectiveness in the Treatment of Pseudomonas aeruginosa Induced Keratitis in Rabbits.
Singh S; Agarwal R; Razak ZA; Ngu R; Nyein LL; Vasudevan S; Kapitonova M; Kadir AJ; Visvaraja S
J Ocul Pharmacol Ther; 2018; 34(1-2):214-223. PubMed ID: 29341837
[TBL] [Abstract][Full Text] [Related]
37. A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.
Chojnacki M; Philbrick A; Scherzi T; Pecora N; Dunman PM; Wozniak RAF
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332071
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Pseudomonas aeruginosa genotype with antibiotic susceptibility and clinical features of induced central keratitis.
Shen EP; Hsieh YT; Chu HS; Chang SC; Hu FR
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):365-71. PubMed ID: 25537202
[TBL] [Abstract][Full Text] [Related]
39. Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Chojnacki M; Philbrick A; Wucher B; Reed JN; Tomaras A; Dunman PM; Wozniak RAF
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30420484
[No Abstract] [Full Text] [Related]
40. Treatment of Pseudomonas keratitis in the rabbit with antibiotic-steroid combinations.
Bohigian GM; Foster CS
Invest Ophthalmol Vis Sci; 1977 Jun; 16(6):553-6. PubMed ID: 405346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
